Comparative Pharmacology
Head-to-head clinical analysis: FOSAMAX versus ZOLEDRONIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAMAX versus ZOLEDRONIC ACID.
FOSAMAX vs ZOLEDRONIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
5 mg intravenously over at least 15 minutes once yearly for Paget disease or osteoporosis; 4 mg intravenously over at least 15 minutes every 3-4 weeks for hypercalcemia of malignancy or multiple myeloma/bone metastases.
None Documented
None Documented
Clinical Note
moderateZoledronic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Zoledronic acid
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zoledronic acid."
Clinical Note
moderateCarprofen + Zoledronic acid
"The risk or severity of adverse effects can be increased when Carprofen is combined with Zoledronic acid."
Clinical Note
moderateTerminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Terminal half-life is approximately 146 hours (6 days), reflecting slow release from bone; clinical effect persists beyond this due to prolonged binding to hydroxyapatite.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Primarily renal (30-40% unchanged in urine over 24h, accounting for ~50% of total clearance); negligible biliary or fecal elimination (<1%).
Category C
Category D/X
Bisphosphonate
Bisphosphonate
Thalidomide + Zoledronic acid
"The risk or severity of adverse effects can be increased when Thalidomide is combined with Zoledronic acid."